

A Real-time 3D Histopathology Imaging Solution for Improved Cancer Diagnosis and Patient Outcomes

Contact person name: Baubak Bajoghli

Organisation: Austrian Biolmaging/CMI

E-mail: baubak.bajoghli@vbcf.ac.at


Link to the IHI brokerage platform:

- Proposal sharing tool
- Participant profile



# Since 1896, the Histopathology is the gold standard for diagnosing cancer

- Around 2 300 000 000 histopathology slides are examined worldwide each year\* this is 72 slides per second
- Despite modernization and workflow optimization over the past 128 years, current histopathology methods do not fully meet the ...
  - Diagnostic needs of cancer patients
  - 2. Align with the demands of 21st-century healthcare systems





# Challenges of current histopathological methodology for a fast and accurate diagnosis of cancer



- ▶ **Timely Diagnosis** Long turnaround time, ~7 days for 70% of patient samples
- Accuracy

- Provides only 2D information results in "histological sampling bias"
- Low accuracy for early carcinoma diagnosis in breast, cervix, thyroid, and brain
- Cost-Effective
- Not aligned with the Green Deal High energy/waste demand



### Our technical solution to solve the problem:

This proposal addresses the IHI specific objective 2



Instead of sending patient samples, 3D images will be sent directly to the pathologist.




Next to the operation rooms



Doctors' offices




# Real-Time 3D Histopathology Imaging





# Real-Time Histopathology Imaging generates 3D images with 94.1% accuracy and 95.4% sensitivity\*

#### Comparison\* Real-Time Paraffin-**Real-Time** Histology embedded Histology Histology **Imaging Imaging** Yes Accuracy Information **Further Analysis** Yes Workflow Very Short Breast Sample **Turnaround Time** 5 minutes **Digital Result** Yes **Cost-Effective** Yes



No



# Contribution of industry/private sector in this proposal



Real-Time Histopathology Imaging – A device with small footprint

Cooperation with Industry and the private sector is required to adopt this innovative technology into a cost-effective, user-friendly device and make it accessible for widespread use in **healthcare systems**.

The contribution of the following sectors is required:

- Medical Devices
- Optical Imaging
- Digital Health
- In vitro Diagnostics
- Medical Technology Regulations



## Outcome and Impacts:

Integrating this technical solution in various healthcare settings, such as **next to operating rooms**, or in **doctors' offices** will result in...

- Outcome: An accurate histopathological diagnosis can be made immediately after collecting the patient's biopsy.
- Impact:
  - For <u>Patients</u>: (1) fast and accurate diagnosis, (2) reducing number of surgeries,
    (3) ensuring the right treatment, (4) reducing unnecessary hospital stays
  - For <u>healthcare systems</u>: (1) reducing costs, (2) more sustainability, (3) aligning with Green Deal
  - For Union's healthcare <u>industry</u>: High competitiveness, the histopathology market is valued at EUR 16 billion in 2023\*



### Expertise and Resources

- We have...
  - Strong expertise in optical imaging
  - Access to pathologists and patients' samples for validation
  - Experience in translational research
  - Access to 237 biological and medical imaging research infrastructures in
    18 European countries through our association with Euro-Biolmaging



### **Expertise and Resources**

- We are looking for partners from the industry/private sector to ...
  - 1) develop the mechanics, lasers, and optical systems for the device
  - 2) develop **software solutions** essential for operating the instrument, enabling real-time imaging and integration with existing digital pathology platforms
  - 3) develop **sample preparation kits**, enhancing compatibility with gold-standard histopathology
  - 4) fulfill the medical technology regulation



# Interested in cooperation?

• You can contact each of the following persons (all are present at the IHI event):



Marco Andreana



marco.andreana@meduniwien.ac.at



Baubak Bajoghli



baubak.bajoghli@vbcf.ac.at



Claudia Pfander



claudia.pfander@eurobioimaging.eu

